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P2-Year Clinical Outcomes After
Implantation of Sirolimus-Eluting,
Paclitaxel-Eluting, and Bare-Metal Coronary Stents
Results From the WDHR (Western Denmark Heart Registry)
Anne Kaltoft, MD, PHD,* Lisette Okkels Jensen, MD, PHD,† Michael Maeng, MD, PHD,*
Hans Henrik Tilsted, MD,‡ Per Thayssen, MD, DMSCI,† Morten Bøttcher, MD, PHD,*
Jens Flensted Lassen, MD, PHD,* Lars Romer Krusell, MD,* Klaus Rasmussen, MD, DMSCI,‡§
Knud Nørregaard Hansen, MD,* Lars Pedersen, MSC, Søren Paaske Johnsen, MD, PHD,§
Henrik Toft Sørensen, MD, PHD, DMSCI,¶ Leif Thuesen, MD, DMSCI*
Aarhus, Odense, and Aalborg, Denmark; and Boston, Massachusetts
Objectives This registry study assessed the safety and efficacy of the 2 types of drug-eluting stents (DES), sirolimus-eluting stents
(SES) and paclitaxel-eluting stents (PES), compared with bare-metal stents (BMS).
Background Drug-eluting stents may increase the risk of stent thrombosis (ST), myocardial infarction (MI), and death.
Methods A total of 12,395 consecutive patients with coronary intervention and stent implantation recorded in the Western
Denmark Heart Registry from January 2002 through June 2005 were followed up for 2 years. Data on death and MI
were ascertained from national medical databases. We used Cox regression analysis to control for confounding.
Results The 2-year incidence of definite ST was 0.64% in BMS patients, 0.79% in DES patients (adjusted relative risk [RR]:
1.09; 95% confidence interval [CI]: 0.72 to 1.65), 0.50% in SES patients (adjusted RR: 0.63, 95% CI: 0.35 to 1.15),
and 1.30% in PES patients (adjusted RR: 1.82, 95% CI: 1.13 to 2.94). The incidence of MI was 3.8% in BMS-treated
patients, 4.5% in DES-treated patients (adjusted RR: 1.24, 95% CI: 1.02 to 1.51), 4.1% in SES-treated patients (ad-
justed RR: 1.15, 95% CI: 0.91 to 1.47), and 5.3% in PES-treated patients (adjusted RR: 1.38, 95% CI: 1.06 to 1.81).
Whereas overall 2-year adjusted mortality was similar in the BMS and the 2 DES stent groups, 12- to 24-month mor-
tality was higher in patients treated with PES (RR 1.46, 95% CI: 1.02 to 2.09). Target lesion revascularization was
reduced in both DES groups.
Conclusions During 2 years of follow-up, patients treated with PES had an increased risk of ST and MI compared with those
treated with BMS and SES. Mortality after 12 months was also increased in PES patients. (J Am Coll Cardiol 2009;
53:658–64) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.058i
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ccepted September 22, 2008.n preventing coronary restenosis (1– 4), but may predis-
ose to stent thrombosis through incomplete tissue
overage of the stent struts. Although the first random-
zed clinical trials comparing DES and BMS raised no
afety concerns (5–7), long-term DES performance was
uestioned in studies reporting an increased risk of
yocardial infarction (MI) and death in DES-treated
atients (8 –11).
See page 665
An important question in the BMS versus DES contro-
ersy is the class effect issue of DES treatment, because
here are major differences between the first commercialized
ES, the Cypher sirolimus-eluting stent (SES) (Cypher,
ordis Corp., Johnson & Johnson, Warren, New Jersey),
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February 24, 2009:658–64 DES and BMS in Western Denmarknd the Taxus paclitaxel-eluting stent (PES) (Boston Sci-
ntific, Natick, Massachusetts) (5,8,10).
In an earlier publication (12), we observed an increased risk
f stent thrombosis 12 to 15 months after implantation. In the
resent study, we extended the follow-up period to 2 years and
ddressed the possible DES class effect issue by reporting
eparate data on patients treated with SES or PES.
ethods
etting and design. The cohort study’s data originate from
he WDHR (Western Denmark Heart Registry) and other
ational databases. The WDHR collects patient- and
rocedure-specific information on coronary interventions per-
ormed at the 3 coronary intervention centers in Western
enmark (Odense University Hospital, Aarhus University
ospital, Skejby, and Aarhus University Hospital, Aalborg).
ational databases include the Danish Civil Registration
ystem, the National Registry of Causes of Deaths, and the
ational Patient Registry, covering the region’s population
approximately 3 million inhabitants, 55% of the Danish
opulation). A detailed description of these databases has been
ublished previously (12). All patients in the cohort were
ollowed up for 2 years.
atients and procedures. We used the WDHR to identify
ll percutaneous coronary interventions (PCIs) between Janu-
ry 1, 2002, and June 30, 2005. For each patient we included
nly the first PCI procedure performed during the study period
the index procedure). The stents were selected at the opera-
ors’ discretion. The indication for the use of DES changed
ver time, from restenosis-prone patients/lesions at the begin-
ing of the study period to an all-comers use. There was no
ifference in recommendations for the use of SES and PES.
e excluded patients receiving balloon angioplasty without
tent implantation or a combination of BMS and DES (n 
45, 4.9%). In the analyses of SES and PES, we excluded
atients receiving both stent types (n  48, 0.04%). Post-PCI
ntiplatelet regimens included lifelong acetylsalicylic acid (75
o 150 mg daily) and clopidogrel with a loading dose of 300 mg
ollowed by 75 mg daily. Since November 2002, the recom-
ended duration of clopidogrel treatment has been 12 months.
tudy end points and definitions. Study end points were
ime to stent thrombosis, all-cause mortality, cardiac death,
I, and target lesion revascularization (TLR), as previously
eported (12). We used the Academic Research Consortium
ARC) definition of stent thrombosis, with a modification for
robable stent thrombosis (13,14).
We defined new MIs as hospitalization for MI occurring
28 days after the index PCI (15). We ascertained admissions
nd readmissions for MI (International Statistical Classifica-
ion of Diseases and Related Health Problems-10th Revision,
odes I21 to I21.9) from the Danish National Patient Registry
12) and deaths from the Civil Registration System. We used
he original death certificates obtained from the National
egistry of Causes of Deaths to classify deaths according toheir underlying cause. tFrom the WDHR we ascer-
ained TLR, defined as a repeat
CI or coronary artery bypass
rafting, occurring within 2 years
fter the index stent implanta-
ion. We assessed all clinical end
oints occurring within 2 years of
he index PCI. An expert com-
ittee reviewed relevant records
nd adjudicated the end points
egarding stent thrombosis and
ause of death.
ovariates. We retrieved data
rom the WDHR on potential
redictors of subsequent cardio-
ascular events, including patient
haracteristics, procedures per-
ormed, and lesion type. We ob-
ained hospital diagnoses for each
atient from the National Patient
egistry from 1977 until the date
f stent implantation, and com-
uted the patients’ Charlson Co-
orbidity Index scores, covering
9 major disease categories (16).
Data were more than 95% complete for patient and
rocedure characteristics and 100% complete for the clinical
nd points (stent thrombosis, death, and MI).
tatistical analysis. We estimated the cumulative incidence
or each end point in the presence of competing risk. We used
ox proportional hazards regression to compute hazard ratios
HRs) as a measure of the relative risks (RRs) for each end
oint. Because the hazards were not proportional throughout
he follow-up period, we computed the HR estimates within
eparate time windows, for which the proportionality assump-
ion held. The HRs in these subanalyses reflected the risk
mong patients alive and at risk of a given end point at the start
f each time period. In regression analyses, we controlled for
ge, sex, diabetes mellitus, PCI indication, and procedure time.
o improve the precision of the estimates, we used the
hange-in-estimate method, in which we retained only those
ariables that changed HR estimates for an outcome by more
han 10% (17). In the lesion-specific analyses (stent thrombosis
nd TLR), we also adjusted for stent length and reference
essel size.
We compared distributions of continuous variables with
ither the 2-sample t test or the Mann-Whitney U test,
epending on whether data conformed to a normal distribu-
ion. We compared distributions of categorical variables using
he chi-square test. We used SAS software version 9.13 (SAS
nstitute Inc., Cary, North Carolina) to analyze the data.
esults
escriptive data. The study encompassed 12,395 consecu-
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RR  relative risk
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularization
WDHR  Western Denmark
Heart Registryive patients with 17,152 lesions. Of these, 3,500 patients with
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DES and BMS in Western Denmark February 24, 2009:658–64,417 lesions received DES, either SES (n 3,426, 63.2%) or
ES (n  1,991, 36.8%), and 8,847 patients with 11,730
esions were treated with BMS. The patients’ median age was
4 years (interquartile range 56 to 72 years), 16% of patients
ere older than 75 years, and 13% had diabetes mellitus.
ndications for PCI were ST-segment elevation myocardial
nfarction (STEMI) (30%), non–STEMI/unstable angina
30%), stable angina (37.0%), and other (3%). Baseline patient,
rocedure, and lesion characteristics differed substantially be-
ween the DES and BMS groups, but were similar in the SES
nd PES groups (Tables 1 and 2).
efinite stent thrombosis. The incidence of definite stent
hrombosis was similar in the DES- and BMS-treated groups,
ith definite stent thrombosis occurring in 43 lesions in 43
atients treated with DES (2-year incidence 0.79%) and in 75
esions in 75 patients treated with BMS (2-year incidence
.64%, adjusted RR: 1.09, 95% confidence interval [CI]: 0.72
o 1.65). The incidence of acute, subacute, and late definite
tent thrombosis also was similar in the 2 groups (Fig. 1A).
ery late definite stent thrombosis occurred in 13 lesions in 13
atients in the DES group (2-year incidence 0.24%) and in 5
esions in 5 patients in the BMS group (2-year incidence
.04%, adjusted RR: 5.25, 95% CI: 1.84 to 14.98) (Table 3).
one of the 118 cases of definite stent thrombosis occurred in
aphenous vein grafts.
atient and Procedure Characteristics in Patients Treated WithES or BMS in Western Denmark From January 2002 Through June
Table 1 Patient and Procedure Characteristics in Patients TreaDES or BMS in Western Denmark From January 2002 T
BMS DES
Number of patients* 8,847 3,500
Male* 6,375 (72.1) 2,533 (72.4)
Age, yrs† 64.2  11.4 61.7  11.2
Family history* 3,191 (36.1) 1,401 (40.0)
Smoking* 3,064 (34.6) 1,179 (33.7)
Diabetes mellitus* 982 (11.1) 593 (16.9)
Hypertension* 3,062 (34.6) 1,401 (40.0)
Previous CABG* 483 (5.5) 237 (6.8)
Previous PCI* 739 (8.4) 340 (9.7)
Previous MI* 2,338 (26.4) 791 (22.6)
Lipid-lowering treatment* 3,322 (37.6) 1,731 (49.5)
Procedure time, min‡ 22.0 (15.0–35.0) 25.0 (15.0–40.0)
Fluoroscopy time, min‡ 7.3 (4.2–12.4) 8.1 (4.9–14.0)
Contrast, ml‡ 125.0 (90.0–200.0) 130 (90.0–200.0)
Number of treated lesions, n‡ 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Indication for PCI*
Stable AP 2,974 (33.6) 1,585 (45.3)
Non-STEMI/UAP 2,710 (30.6) 1,042 (29.8)
STEMI 2,946 (33.3) 759 (21.7)
Other 217 (2.5) 114 (3.3)
Comorbidity index score*
0 5,403 (61.1) 2,029 (58.0)
1–2 2,690 (30.4) 1,105 (31.6)
3 754 (8.5) 366 (11.5)
n or n (%). Comparison made using the chi-square test. †Mean (standard deviation). Compar
ann-Whitney U test.
AP  angina pectoris; BMS  bare-metal stent(s); CABG  coronary artery bypass graft; DES  drug-
ntervention; PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); STEMI  ST-segment eleAnalyzing the SES and PES groups separately revealed
ifferent risks of stent thrombosis. The SES group did not
ignificantly differ from the BMS group with respect to definite
tent thrombosis, whereas the PES group had a substantially
ncreased risk.
redictors of definite stent thrombosis. The risk of defi-
ite stent thrombosis was increased by STEMI (adjusted RR:
.14, 95% CI: 1.93 to 5.10), stent length (adjusted RR per
dditional millimeter of stent length: 1.02, 95% CI: 1.00 to
.05), and procedure time (adjusted RR per additional minute
f procedure time: 1.01, 95% CI: 1.00 to 1.02).
efinite stent thrombosis and antiplatelet therapy. Among
he 118 patients in whom definite stent thrombosis devel-
ped, 92 (78%) were treated with dual antiplatelet therapy
aspirin and clopidogrel) at the time of the thrombotic
vent. In the 18 patients with very late stent thrombosis, 3
atients (17%) were receiving dual antiplatelet therapy, 11
atients (61%) were treated with aspirin only, and 4 patients
22%) had discontinued both aspirin and clopidogrel.
efinite, probable, or possible stent thrombosis. Defi-
ite, probable, or possible stent thrombosis was found in 81
atients treated with DES (2-year incidence 2.28%) and in 218
atients treated with BMS (2-year incidence 2.46%, RR: 1.07,
5% CI: 0.82 to 1.39). After controlling for covariates, the risk
f stent thrombosis (definite, probable, or possible) did not
5
ith
gh June 2005
BMS vs. DES
p Value SES PES
SES vs. PES
p Value
0.05 2,202 1,298 NS
0.05 1,571 (71.3) 962 (74.1) NS
0.05 61.7  11.2 61.8  11.3 NS
0.05 846 (38.4) 555 (42.8) NS
0.05 722 (32.8) 457 (35.2) NS
0.05 367 (16.7) 226 (17.4) NS
0.05 868 (39.4) 533 (41.1) NS
0.05 142 (6.5) 95 (7.3) NS
0.05 211 (9.6) 129 (9.9) NS
0.05 506 (23.0) 285 (22.0) NS
0.05 1,053 (47.8) 678 (52.2) NS
0.05 25.0 (15.0–40.0) 24.0 (15.0–37.0) NS
0.05 8.2 (4.9–14.5) 8.0 (5.0–13.5) NS
0.05 135 (90.0–200.0) 130 (90–200) NS
0.05 1.0 (1.0–2.0) 1.0 (1.0–2.0) NS
0.05 0.05
1,049 (47.6) 536 (41.3)
631 (28.7) 411 (31.7)
455 (20.7) 304 (23.4)
67 (3.0) 47 (3.6)
0.05 0.05
1,280 (58.1) 549 (42.3)
718 (32.6) 387 (29.8)
204 (9.3) 162 (12.5)
de using the Student t test. ‡Median (25% to 75% percentiles). Comparison made using the200
ted W
hrou
ison maeluting stent(s); MI  myocardial infarction; NS  not significant; PCI  percutaneous coronary
vation myocardial infarction; UAP  unstable angina pectoris.
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February 24, 2009:658–64 DES and BMS in Western Denmarkiffer between the 2 groups (adjusted RR: 1.03, 95% CI: 0.79
o 1.34) (Table 4).
Within the DES group, definite, probable, or possible stent
hrombosis was found in 38 patients treated with SES (2-year
ncidence 1.73%) and in 43 patients treated with PES (2-year
ncidence 3.31%). After controlling for covariates, the risk of
tent thrombosis was not increased in the SES group compared
ith the BMS group, but there was an increased risk in the
ES group compared with the BMS group (adjusted RR:
.44, 95% CI: 1.03 to 2.01) (Table 4).
ortality. All-cause 2-year mortality was lower among
ES-treated than BMS-treated patients (6.40% vs. 7.86%, log
ank p  0.0053), (Fig. 1B). After controlling for covariates,
his difference disappeared (adjusted RR: 0.97, 95% CI: 0.83 to
.13). Overall 2-year cardiac mortality was also lower among
ES than among BMS patients (2.99% vs. 4.36%, log rank
 0.0006). After adjustment, risk of cardiac death no longer
iffered in the 2 groups (adjusted RR: 0.87, 95% CI: 0.69 to
.08). Noncardiac 2-year mortality was similar in the DES
3.24%) and BMS groups (3.47%), log-rank p  0.46 (ad-
usted RR: 1.04, 95% CI: 0.82 to 1.33). During the second half
f the follow-up period (12 to 24 months), all-cause mortality
as higher among patients treated with DES than among
hose treated with BMS (adjusted RR: 1.33, 95% CI: 1.02 to
.72). This increase was primarily driven by an increase in
ortality in the PES group (adjusted RR: 1.46, 95% CI: 1.02
o 2.09) (Table 4).
yocardial infarction. The 2-year incidence of MI was
imilar in the 3 stent groups (DES 4.5% vs. BMS 3.8%,
og-rank p  0.1022). However, after controlling for covari-
esions Treated With DES or BMS in Western Denmark From Janua
Table 2 Lesions Treated With DES or BMS in Western Denmark
BMS DES BM
Number of lesions 11,730 5,417
Vessel*
RCA 4,684 (39.9) 1,385 (25.6)
LAD 4,258 (36.3) 2,810 (51.9)
LCX 2,680 (22.9) 1,034 (19.1)
LM 98 (0.8) 188 (3.5)
Saphenous vein graft* 134 (1.1) —
Lesion length, mm† 12.0 (10.0–16.0) 14.0 (10.0–20.0)
Lesion type*
A 2,554 (21.8) 1,149 (21.2)
B1 6,908 (58.9) 2,167 (40.0)
B2 1,312 (11.2) 516 (9.5)
C 948 (8.1) 1,585 (29.3)
Restenotic lesion* 118 (1.0) 129 (2.4)
Stent length, mm† 15.0 (12.0–18.0) 18.0 (13.0–24.0)
Stent number, n† 1.0 (1.0–1.0) 1.0 (1.0–1.0)
Maximum balloon pressure, atm† 15.0 (12.0–18.0) 15.0 (14.0–18.0)
Maximum balloon diameter, mm† 3.5 (3.0–3.8) 3.3 (3.0–3.7)
Reference segment, mm† 3.3 (3.0–3.7) 3.1 (2.9–3.5)
Minimum lumen diameter, mm† 0.3 (0.0–0.7) 0.3 (0.0–0.7)
Stenosis, % of luminal diameter† 90.0 (88.0–99.0) 90.0 (80.0–99.0)
n (%). Comparison made using chi-square test. †Median (25% to 75% percentiles). Comparison
LAD  left anterior descending artery; LCX  left circumflex artery; LM  left main artery; RCAtes, the DES group had an increased risk of MI (adjusted RR: D.24, 95% CI: 1.02 to 1.51), primarily because of an increase in
I events after 12 months of follow-up in the PES group (Fig.
C, Table 4).
LR. Target lesion revascularization occurred less frequently
mong DES-treated than among BMS-treated patients (2-
ear incidence 5.3% vs. 7.9%, log-rank p  0.0001). After
ontrolling for age, sex, clinical presentation, diabetes mellitus,
tent length, and reference vessel size, the absolute risk reduc-
ion among patients in the DES compared with the BMS
roup was 44% (adjusted RR: 0.56, 95% CI: 0.49 to 0.65). In
he SES group the risk reduction was 51% (adjusted RR: 0.49,
5% CI: 0.41 to 0.59), and in the PES group the risk reduction
as 32% (adjusted RR: 0.68, 95% CI: 0.56 to 0.83) (Fig. 1D).
iabetes mellitus (adjusted RR: 1.43, 95% CI: 1.22 to 1.69),
TEMI (adjusted RR: 1.35, 95% CI: 1.16 to 1.58), and stent
ength (adjusted RR per additional millimeter of stent length:
.02, 95% CI: 1.01 to 1.03) increased the risk of TLR, whereas
ize of the reference vessel was inversely related to TLR risk
adjusted RR per decreasing millimeter of vessel diameter:
.73, 95% CI: 0.65 to 0.81).
iscussion
n this large population-based 2-year follow-up study, patients
reated with either DES or BMS had similar rates of death and
tent thrombosis, whereas the DES group had an increased
isk of MI. During the last year of follow-up, rates of stent
hrombosis, MI, and death were significantly increased in DES
atients because of increased event rates in patients treated
ith PES. Further, clinically driven TLR was 39% lower in the
02 Through June 2005
m January 2002 Through June 2005
DES p Value SES PES SES vs. PES p Value
3,426 1,991
0.05 0.05
835 (24.4) 550 (27.6)
1,828 (53.4) 982 (49.3)
680 (19.9) 354 (17.8)
83 (2.4) 105 (5.3)
0.05 — — NS
0.05 15.0 (10.0–20.0) 12.0 (10.0–20.0) 0.05
0.05 0.05
723 (21.1) 426 (21.4)
1,320 (38.5) 847 (42.5)
381 (11.1) 135 (6.8)
1,002 (29.3) 583 (29.3)
0.05 76 (2.7) 53 (2.9) NS
0.05 18.0 (13.0–23.0) 16 (12–24) 0.05
0.05 1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.05
0.05 16.0 (14.0–19.0) 15.0 (12.0–18.0) 0.05
0.05 3.2 (3.0–3.5) 3.4 (3.0–3.7) 0.05
0.05 3.0 (2.8–3.5) 3.3 (3.0–3.7) 0.05
NS 0.3 (0.0–0.6) 0.3 (0.0–0.7) 0.05
0.05 90.0 (80.0–99.0) 90.0 (80.0–99.0) NS
sing Mann-Whitney U test.
t coronary artery; other abbreviations as in Table 1.ry 20
Fro
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

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DES and BMS in Western Denmark February 24, 2009:658–64The lack of adequately powered randomized clinical end
oint trials comparing BMS with DES prompted interven-
ional cardiologists to assess the safety and efficacy of DES
sing registries and meta-analyses (18,19). Data from the
wedish Coronary Angiography and Angioplasty Registry
SCAAR) on PCI patients from 2003 and 2004, published in
Figure 1 Clinical Outcome: Unadjusted Data
(A) Definite stent thrombosis. Risk of definite stent thrombosis among patients tr
stents (BMS). (B) All-cause mortality. All-cause mortality among patients treated w
treated with SES, PES, or BMS. (D) Target lesion revascularization (TLR). Risk of T
ncidence Rate and RR of Definite Stent Thrombosis in Lesions TreES  3,426, PES  1,991) or BMS (  11,730) in W tern Den
Table 3 Incidence Rate and RR of Definite Stent Thrombosis inSES  3,426, PES  1,991) or BMS (n  11,730) in
Number of Events
BMS DES SES PES DES
All 75 43 17 26 1.07 (
Acute (24 h) 12 8 5 3 0.91 (
1 to 30 days 46 15 7 8 0.68 (
30 days to 1 yr 12 7 1 6 0.98 (
1 yr 5 13 4 9 5.15 (Adjusted for age, STEMI, stent length, and procedure time.
CI  confidence interval; RR  relative risk; other abbreviations as in Table 1.he New England Journal of Medicine in 2007, indicated that
ES was associated with an increased risk of death and MI
ompared with BMS (8). More recent data from SCAAR,
ncluding patients registered in 2005 (reported at the 2007
eetings of the European Society of Cardiology and the
nnual Scientific Symposium of Transcatheter Cardiovascular
with sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES), or bare-metal
S, PES, or BMS. (C) Myocardial infarction (MI). Risk of MI among patients
ong patients treated with SES, PES, or BMS.
With DES (n  5,422,From January 200 Through June 2005
ons Treated With DES (n  5,422,
ern Denmark From January 2002 Through June 2005
RR* (95% CI)
MS SES vs. BMS PES vs. BMS SES vs. PES
.61) 0.61 (0.33–1.11) 1.75 (1.09–2.82) 0.35 (0.18–0.69)
.60) 0.86 (0.24–3.08) 0.93 (0.21–4.19) 0.94 (0.16–5.62)
.27) 0.53 (0.24–1.19) 0.87 (0.39–1.93) 0.62 (0.22–1.78)
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February 24, 2009:658–64 DES and BMS in Western Denmarkherapeutics), showed no difference in overall mortality or risk
f MI associated with the 2 types of stents, i.e., a pattern
imilar to our data. Coronary interventional revascularization
herapy is organized differently in Sweden and Denmark,
entralized in Denmark and decentralized in Sweden. Whereas
se of DES was uniformly high in Denmark, use of DES
anged from 0.5% to 60% among Swedish centers (8). Also,
ES was more widely used in Sweden than in our population.
mportantly, the Swedish recommendations for dual antiplate-
et therapy varied from 3 to 6 months for DES and 1 month
or BMS, versus the uniform Danish recommendation of 12
onths (8). Data from both registries showed a change in the
lopes of stent thrombosis and MI curves over time in
ES-treated patients. This occurred at 6 months in the
CAAR and at 12 months in the WDHR. This may be
xplained by the difference in duration of dual antiplatelet
herapy.
Stettler et al. (20) published a network meta-analysis includ-
ng 36 randomized trials on PES and SES, and found better
afety and efficacy for SES compared with PES. In contrast to
he present study, their analysis mainly included selected
atients with relatively simple coronary artery lesions and
atients with stable angina pectoris. Nevertheless, our
opulation-based results, including both simple and complex
oronary artery lesions and patients with stable and unstable
oronary syndromes, were in line with this large meta-analysis.
The recently published Danish multicenter trial, the SORT
UT II (Danish Organization on Randomized Trials With
linical Outcome) study, randomized 2,098 patients in a
ead-to-head comparison of SES and PES (21). Although the
ates of death, MI, new revascularization, and ARC-defined
tent thrombosis were higher in PES-treated patients than in
ES-treated patients in the SORT OUT II study, the differ-
R Estimates for Death, Myocardial Infarction, and Stent Thrombond Possibl ) Among Patients Tre ted With BMS (n  8,847) or D
Table 4 RR Estimates for Death, Myocardial Infarction, and Steand Possible) Among Patients Treated With BMS (n 
n (%)
BMS SES PES
All-cause death 695 (7.9) 130 (5.9) 95 (7.3)
12 months 503 (5.7) 81 (3.7) 59 (4.6)
12 months 192 (2.2) 49 (2.2) 36 (2.8)
Cardiac 386 (4.4) 65 (3.0) 41 (3.2)
Noncardiac 261 (3.0) 51 (2.3) 45 (3.5)
Myocardial infarction 329 (3.8) 88 (4.1) 67 (5.3)
28 days to 12 months 238 (2.8) 51 (2.4) 36 (2.8)
12 months 91 (1.1) 37 (1.7) 31 (2.4)
Overall ST 218 (2.5) 38 (1.7) 43 (3.3)
Acute (24 h) 23 (0.3) 4 (0.2) 4 (0.3)
1 to 30 days 99 (1.1) 12 (0.5) 12 (0.9)
30 days to 12 months 57 (0.6) 11 (0.5) 15 (1.2)
12 months 39 (0.4) 11 (0.5) 12 (0.9)
Probable ST 68 (0.8) 6 (0.3) 5 (0.4)
Possible ST 81 (0.9) 19 (0.9) 13 (1.0)
Adjusted for age, sex, diabetes, clinical indication, and procedure time.
ST  stent thrombosis; other abbreviations as in Tables 1 and 3.nces did not reach statistical significance.
*The SES and the PES were the first widely used and until
ecently the only DES approved by the U.S. Food and Drug
dministration. Apart from the drug released from the stents,
here are marked differences in release kinetics and polymer
oating. In the PES, the active drug, paclitaxel, is homoge-
eously distributed in the polymer. In the SES, sirolimus is
laced in a base coating and released through a permeable top
oating (22). In studies with angiographic follow-up, the late
oss of the PES was about 0.3 mm, versus 0.1 mm for the SES
23). This difference in neointimal formation was found to be
ranslated into an increased rate of new revascularization in
tudies using angiographic follow-up (24), meta-analysis (20),
r as in the present study, registries.
It might be anticipated that some degree of late loss and
ptimal neointimal coverage of stent struts would be protective
gainst late stent thrombosis, and consequently, that PES
reatment would be associated with a lower risk of stent
hrombosis compared with SES treatment. However, such a
efinite, Probable, 3,548) in W stern Denmark
hrombosis (Definite, Probable,
7) or DES (n  3,548) in Western Denmark
RR* (95% CI)
S vs. BMS SES vs. BMS PES vs. BMS SES vs. PES
(0.83–1.13) 0.88 (0.73–1.07) 1.03 (0.82–1.28) 0.86 (0.66–1.13)
(0.69–1.01) 0.82 (0.64–1.04) 0.87 (0.66–1.15) 0.89 (0.63–1.25)
(0.87–1.48) 1.04 (0.75–1.45) 1.46 (1.02–2.09) 0.81 (0.52–1.26)
(0.69–1.08) 0.87 (0.66–1.14) 0.82 (0.59–1.14) 1.07 (0.71–1.59)
(0.82–1.33) 0.83 (0.61–1.15) 1.24 (0.90–1.71) 0.67 (0.44–1.01)
(1.02–1.51) 1.15 (0.91–1.47) 1.38 (1.06–1.81) 0.82 (0.59–1.13)
(0.73–1.22) 0.98 (0.72–1.34) 1.02 (0.71–1.48) 0.95 (0.61–1.47)
(1.47–2.79) 1.60 (1.08–2.37) 2.36 (1.56–3.56) 0.68 (0.42–1.10)
(0.79–1.34) 0.80 (0.56–1.14) 1.44 (1.03–2.01) 0.54 (0.35–0.85)
(0.39–1.73) 0.80 (0.31–2.07) 1.00 (0.35–2.85) 0.79 (0.21–2.94)
(0.45–1.14) 0.60 (0.32–1.13) 1.03 (0.56–1.89) 0.57 (0.25–1.30)
(0.74–1.94) 0.82 (0.42–1.62) 1.83 (1.01–3.29) 0.44 (0.20–1.00)
(1.01–2.88) 1.19 (0.61–2.35) 2.14 (1.11–4.11) 0.55 (0.24–1.25)
(0.26–0.95) 0.48 (0.21–1.12) 0.60 (0.24–1.51) 0.78 (0.24–2.56)
(0.77–1.78) 1.02 (0.61–1.71) 1.11 (0.61–2.01) 0.88 (0.43–1.81)
R Estimates of Definite ST and Mortalityn Le ions Treated With DES (  5,422,ES  3,426, PES  1,991) or BMS (n  11,730),umulative Time P riods
Table 5
RR Estimates of Definite ST and Mortality
in Lesions Treated With DES (n  5,422,
SES  3,426, PES  1,991) or BMS (n  11,730),
Cumulative Time Periods
RR* (95% CI)
DES vs. BMS SES vs. PES
Definite ST
0–1 day 0.91 (0.32–2.60) 0.94 (0.16–5.62)
0–30 days 0.73 (0.43–1.23) 0.69 (0.28–1.71)
0–1 yr 0.77 (0.48–1.23) 0.45 (0.20–1.00)
0–2 yrs 1.07 (0.71–1.61) 0.35 (0.18–0.69)
All-cause death
0–1 yr 0.84 (0.69–1.01) 0.89 (0.63–1.25)
0–2 yrs 0.97 (0.83–1.13) 0.86 (0.66–1.13)sis (DES (n
nt T
8,84
DE
0.97
0.84
1.13
0.87
1.04
1.24
0.94
2.03
1.03
0.82
0.72
1.20
1.71
0.50
1.17Adjusted for age, sex, diabetes, clinical indication, and procedure time.
Abbreviations as in Tables 1, 3, and 5.
r
a
t
o
t
a
f
c
e
d
t
b
m
p
o
S
t
d
d
u
c
t
b
a
t
r
t
t
a
C
D
h
p
i
a
l
w
o
P
e
t
R
p
B
a
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
664 Kaltoft et al. JACC Vol. 53, No. 8, 2009
DES and BMS in Western Denmark February 24, 2009:658–64elationship has never been shown. In contrast, the meta-
nalysis from Stettler et al. (20) and the present study showed
hat PES, and not SES, was associated with an increased risk
f late stent thrombosis. Therefore, the drug release kinetics,
he drug itself, the polymer, or other characteristics of the PES
re likely to predispose to stent thrombosis.
The SES and PES have been thought to behave identically
rom a clinical perspective. Until recently, DES has been
onsidered as one stent type in registry studies (8,12), and the
ffect of DES was considered a class effect. The present study
ocuments the importance of distinguishing between different
ypes of DES. This may complicate stent treatment of patients,
ut it also raises the possibility that this first generation of DES
ay be optimized by modifying stent platform, drug, or
olymer, thereby improving short-term and long-term results
f future DES treatment.
tudy limitations. The recommended duration of dual an-
iplatelet treatment was 12 months, but data on the actual
uration of this treatment were available only for patients with
efinite stent thrombosis. Another concern is that we were
nable to disaggregate MI events by area of infarction and thus
ould not include MI in the ARC definition of probable stent
hrombosis.
According to the ARC definition of probable and possi-
le stent thromboses, we categorized any unexplained death
s stent thrombosis. However, it is unlikely that stent
hrombosis caused all unexplained deaths.
In the analyses of stent thrombosis and mortality, we have
eported the relative risk estimates at various left-truncated
ime periods, which might bias the point estimates. Therefore,
he cumulative statistics at various right-censored time points
re reported in Table 5.
onclusions
uring a 2-year follow-up period, patients treated with SES
ad similar risks of stent thrombosis and MI compared with
atients treated with BMS, and those treated with PES had an
ncreased risk of these outcomes. Death after 12 months was
lso higher in PES-treated patients. Clinically driven TLR was
ower in both DES groups compared with the BMS group,
ith lowest rates in SES-treated patients. Our data indicate an
verall better safety and efficacy profile of the SES than the
ES, and show that the effect of DES treatment is not a class
ffect. This raises the possibility of improving future genera-
ions of DES.
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